Who
Mary T. Szela
CEO and President
Company insider
Files Form 4 as: CEO and President, TriSalus Life Sciences; Director, Absci; Director, Kura Oncology; Director, Omega Therapeutics; Director, Prometheus Biosciences; Director, Coherus Oncology; Director, Alimera Sciences; Chief Executive Officer, Novelion Therapeutics.
In numbers
- Trades disclosed
- 228
- Buys
- 10
- Sells
- 17
- Bought
- $956K
- Sold
- $8.2M
- Companies
- 11
- Companies where not an officer
- 7
- First trade
- 27 Aug 2007
- Last trade
- 5 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 7 Oct 2026 | TLSI TriSalus Life SciencesMedical Devices | SEC FORM 4 Code F | $12K2,693 at $4.38 | filing |
| 30 Jun 2026filed 6 Jul 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Bought | $149K12,900 at $11.54 | filing |
| 30 Jun 2026filed 6 Jul 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Bought | $149K12,900 at $11.54 | filing |
| 30 Jun 2026filed 1 Jul 2026 | TLSI TriSalus Life SciencesMedical Devices | SEC FORM 4 Code A | $15K3,990 at $3.87 | filing |
| 30 Jun 2026filed 1 Jul 2026 | TLSI TriSalus Life SciencesMedical Devices | SEC FORM 4 Code A | $15K3,990 at $3.87 | filing |
| 4 Jun 2026filed 15 Jun 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Code A | —8,400 at $0.00 | filing |
| 4 Jun 2026filed 15 Jun 2026 | ABSI Abscioption or derivative · Life-science tools | SEC FORM 4 Code A | —33,200 at $0.00 | filing |
| 4 Jun 2026filed 15 Jun 2026 | ABSI Abscioption or derivative · Life-science tools | SEC FORM 4 Code A | —33,200 at $0.00 | filing |
| 4 Jun 2026filed 15 Jun 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Code A | —8,400 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Code A | —10,100 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ABSI Abscioption or derivative · Life-science tools | SEC FORM 4 Code A | —39,800 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ABSI Abscioption or derivative · Life-science tools | SEC FORM 4 Code A | —39,800 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ABSI AbsciLife-science tools | SEC FORM 4 Code A | —10,100 at $0.00 | filing |
| 4 Jun 2026filed 4 Jun 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 4 Jun 2026filed 4 Jun 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 15 May 2026filed 18 May 2026 | TLSI TriSalus Life SciencesMedical Devices | SEC FORM 4 Bought | $103K39,682 at $2.59 | filing |
| 15 May 2026filed 18 May 2026 | TLSI TriSalus Life SciencesMedical Devices | SEC FORM 4 Bought | $103K39,682 at $2.59 | filing |
| 17 Mar 2026filed 20 Mar 2026 | TLSI TriSalus Life SciencesMedical Devices | SEC FORM 4 Sold | $61K15,944 at $3.85 | filing |
| 17 Mar 2026filed 20 Mar 2026 | TLSI TriSalus Life SciencesMedical Devices | SEC FORM 4 Sold | $61K15,944 at $3.85 | filing |
| 11 Mar 2026filed 20 Mar 2026 | TLSI TriSalus Life SciencesMedical Devices | SEC FORM 4 Sold | $18K4,358 at $4.13 | filing |
News
Absci (NASDAQ:ABSI) Given New $20.00 Price Target at KeyCorpABSI · themarketsdaily.com · 16 Oct 2026Absci (NASDAQ:ABSI) Price Target Raised to $15.00ABSI · dailypolitical.com · 15 Oct 2026Financial Comparison: Brainsway (NASDAQ:BWAY) and TriSalus Life Sciences (NASDAQ:TLSI)TLSI · dailypolitical.com · 14 Oct 2026TriSalus Life Sciences, Inc. (TLSI) – What Are Brokerages Saying About This Stock?TLSI · dailypolitical.com · 11 Oct 2026Denali Therapeutics (NASDAQ:DNLI) and Absci (NASDAQ:ABSI) Head to Head ComparisonABSI · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Mary T. Szela; 5 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.